Humacyte (NASDAQ:HUMA) Holdings, Inc. (NASDAQ: HUMA) is a clinical‐stage biotechnology company dedicated to the development and commercialization of regenerative medicine products designed to address vascular and other tissue disorders. The company’s core offering is the Human Acellular Vessel (HAV), an off‐the‐shelf bioengineered blood vessel manufactured from donated human vascular cells. By providing a sterile, off‐the‐shelf alternative to synthetic grafts and donor tissue, Humacyte aims to improve outcomes for patients in need of vascular access or repair, particularly those with end‐stage renal disease and peripheral artery disease.
Humacyte’s proprietary platform leverages a unique cell cultivation process in which human smooth muscle cells are seeded onto a biodegradable scaffold and matured in a bioreactor. Once implanted, the vessel supports host cell remodeling and integration without the need for long‐term immunosuppression. The HAV is currently advancing through multiple clinical trials, including studies in hemodialysis access, vascular trauma repair and peripheral arterial disease. The company continues to invest in research to expand its pipeline into additional indications such as vascular bypass procedures and cardiovascular reconstruction.
Founded in 2004 as a spinoff from Duke University, Humacyte has steadily progressed from early‐stage research into late‐stage clinical development. Headquartered in Durham, North Carolina, the company collaborates with leading medical centers across the United States and maintains partnerships in Europe and Asia to support international clinical programs and eventual commercialization. Humacyte has built manufacturing facilities capable of scalable production to meet anticipated demand upon regulatory approval.
Humacyte is guided by a leadership team with deep expertise in biotechnology, regenerative medicine and vascular surgery. The company was co‐founded by Laura E. Niklason, M.D., Ph.D., a recognized pioneer in vascular tissue engineering, and is supported by a board of directors and executive officers drawn from prominent pharmaceutical, medical device and academic institutions. Together, they seek to bring transformative therapeutic options to patients suffering from life‐threatening vascular conditions.
